TMO Investor Day: modest downward revision to long-term growth target, but AI, reshoring, and bioprocessing support the Buy thesis

Overview

This report summarizes the key takeaways from Thermo Fisher Scientific Inc.'s 2026 Investor Day. Management updated its 2028-2031+ long-term organic growth target to 7% and introduced targets for 40-50bps of margin expansion and low double-digit adjusted EPS and free cash flow growth. Goldman Sachs believes the scale of the target reduction is limited and has largely already been absorbed by investor expectations, shifting the core focus to how TMO can drive growth reacceleration through AI drug R&D workflows, the reshoring of U.S. pharmaceutical manufacturing capacity, bioprocessing expansion, and a recovery in biotech funding.

Core views

The core views are: first, although the long-term 7% organic growth target is lower than the previous 7%+ and 7-9% wording, FactSet consensus and GSe expectations for high-5% growth in 2028 suggest the market has already priced it in; second, moving from about 3% growth in 2026 to 7% in 2028-2031+ requires both 400-500bps of underlying market growth and 200-300bps of TMO market share gains; third, AI will improve drug discovery, wet-lab validation, clinical trial efficiency, and CDMO demand, and TMO is well positioned to benefit given its broad product portfolio, proprietary data, Clario, and partnerships with Nvidia and OpenAI; fourth, BioProduction and CDMO will benefit from mAb output, innovative biologics modalities, and the reshoring of U.S. pharmaceutical manufacturing capacity.

Analysis framework

The report uses an investor day takeaways approach, cross-validating management's long-term guidance, end-market recovery signals, M&A strengthening, AI use cases, and valuation targets; it also compares management's new targets with prior guidance, FactSet consensus, and GSe expectations to assess the impact of the target reduction on investor expectations.

Methodology notes

• Valuation methodEV/EBITDA

  12-month target price valuation

  Goldman Sachs's $570 target price is based on Q5-Q8 estimates and uses a 19x target EV/EBITDA multiple.

• Growth decompositionLong-term guidance bridge

  From about 3% organic growth in 2026 to the 7% target for 2028-2031+

  The company breaks long-term growth into about 400-500bps of underlying market growth and about 200-300bps of market share gains, relying on drivers such as AI, pharmaceutical reshoring, a recovery in biotech spending, and stabilization in academic markets.

• Factor frameworkGS Factor Profile

  Growth, financial returns, valuation multiples, and composite percentile

  Goldman Sachs Factor Profile compares stocks with the market and industry peers using attributes such as growth, financial returns, and valuation multiples to provide investment context.

• M&A frameworkM&A Rank

  Acquisition probability score

  Goldman Sachs discloses that it uses an M&A Rank of 1 to 3 to assess potential acquisition probability for covered companies; this is a standard disclosure, and the report body does not provide a specific M&A Rank for TMO.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Thermo Fisher Scientific Inc. (TMO)

  Core covered name, rated Buy by Goldman Sachs.

  Strengths

  Broad product portfolio and trusted partner status across Pharma/Biotech workflows, with multiple growth vectors including AI, Clario, CDMO, BioProduction, and analytical instruments.

  Weaknesses

  Current organic growth is about 3%, end-market recovery will take time, and the long-term target has been lowered versus prior wording.

  Comparison

  Management's long-term 7% target is above FactSet consensus and GSe expectations for high-5% organic growth in 2028; covered peers include Agilent Technologies, Danaher, Waters, and others.

  Risks

  Weakness in the early-stage research market, insufficient large pharma spending, downward revisions to long-term plan expectations, and continued weakness in the U.S. A&G market.

• AI drug R&D and clinical research workflow

  A source of demand growth for TMO.

  Strengths

  Higher AI-driven data analysis efficiency requires more wet-lab validation; Clario has more than 100 proprietary AI solutions; partnerships with Nvidia and OpenAI may drive efficiency in automated instruments and clinical workflows.

  Weaknesses

  The pace at which AI demand converts from trials and dataset construction into commercial spending remains uncertain.

  Comparison

  TMO's advantage comes from proprietary data, clinical research history, and broad experimental tools, not just standalone AI software capabilities.

  Risks

  If Pharma/Biotech does not convert AI efficiency into pipeline expansion or CDMO demand, the growth contribution may be lower than expected.

• BioProduction / CDMO / U.S. pharmaceutical reshoring

  A direction for long-term growth and portfolio strengthening.

  Strengths

  BioProduction 2025 pro forma revenue is $3.4bn, the Solventum purification and filtration business fills a portfolio gap, the Sanofi fill-finish site enhances near-term capacity, and CDMO can support clients transitioning to U.S.-based capacity.

  Weaknesses

  Reshoring construction and client capacity migration take time, so near-term growth realization may lag.

  Comparison

  This business reflects TMO's full-service capability from CDMO services to support for clients' future U.S. factories.

  Risks

  If U.S. pharmaceutical reshoring is slower than expected or spending on mAbs and new biologics R&D slows, the assumption that bioprocessing can grow above the market may come under pressure.

Key data

• Report date2026-05-20The cover shows 20 May 2026 | 5:52PM EDT.
• Long-term organic growth target7%Applicable to 2028-2031+, below the previous 7%+ and earlier 7-9% long-term wording.
• Long-term margin expansion target40-50bpsPart of management's long-term targets.
• Adjusted EPS and free cash flow growthlow double digitsThe company's long-term targets include low double-digit adjusted EPS and free cash flow growth.
• 2026-2027 organic growth guidance3-6%This range is maintained even after including Clario and the planned Microbiology divestiture.
• Adjusted operating profit growth+HSDRaised from +MSD to +HSD previously, in line with Goldman Sachs's current estimates.
• Market share gain contributionapproximately 200-300bpsThe long-term growth contribution expected from TMO-specific initiatives.
• Underlying market growth contributionapproximately 400-500bpsThe end-market improvement component in the company's long-term growth bridge.
• BioProduction 2025 pro forma revenue$3.4bnThe report states that this business was strengthened by the Solventum purification and filtration business.
• Target price$570Goldman Sachs 12-month target price, based on Q5-Q8 estimates and 19x target EV/EBITDA.
• Disclosed price$451.79Bracketed price in company-specific regulatory disclosure.
• Implied upsideapproximately 26.2%A simple calculation based on the $570 target price and the $451.79 disclosed price, excluding dividends.

Impact & implications

In terms of investment implications, Goldman Sachs believes TMO's long-term growth story has not been weakened by the 7% target wording; rather, investors should focus on whether AI workflows, bioprocessing, U.S. reshoring, and a recovery in biotech funding can lift current organic growth of about 3% toward the long-term target. If end-market recovery materializes and Clario and Solventum-related assets improve portfolio completeness, TMO's position as a trusted partner and its full-chain service capabilities may support valuation and earnings growth.

Risks

• Weakness in the early-stage research end market may hinder the realization of long-term growth expectations.
• If incremental spending from large pharmaceutical companies is weak, or if additional MFN deals fail to materialize, R&D spending may decline.
• If the path of end-market recovery becomes more uncertain, the market may lower expectations for the long-term plan.
• Continued weakness in the U.S. A&G market is a clear risk.
• The historical lag between higher biotech funding and actual spending, the pace of U.S. pharmaceutical reshoring, and the timing of stabilization in academic markets in the U.S. and China could all affect growth reacceleration.

What to watch

• Whether improved biotech financing can convert into actual experimentation, procurement, and R&D spending.
• Whether the reshoring of U.S. pharmaceutical manufacturing capacity drives demand for CDMO, fill-finish, and bioprocessing.
• The commercialization progress of Clario integration and its more than 100 proprietary AI solutions in clinical research.
• Whether Nvidia-partnered fully automated instruments and OpenAI-partnered clinical workflow applications can progress as planned.
• Whether demand for analytical instruments is driven by AI drug discovery and wet-lab validation demand.
• When academic end markets in the U.S. and China will stabilize.
• Whether 3-6% organic growth and +HSD adjusted operating profit growth in 2026-2027 can be delivered.